BDTX Black Diamond Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: BDTX

Price (delayed)

$5.06

Market cap

$261.69M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.88

Enterprise value

$226.83M

Black Diamond Therapeutics is a precision oncology medicine company pioneering the discovery of small molecule, tumor-agnostic therapies. Black Diamond targets undrugged mutations in patients with genetically defined cancers. Black Diamond ...

Highlights
Black Diamond Therapeutics's EPS has increased by 25% YoY and by 12% QoQ
The debt has declined by 12% year-on-year and by 3.5% since the previous quarter
The quick ratio has contracted by 30% from the previous quarter and by 17% YoY
The company's equity fell by 13% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.blackdiamondtherapeutics.com
Peers: OMER OMGA

Key stats

What are the main financial stats of BDTX
Market
Shares outstanding
51.72M
Market cap
$261.69M
Enterprise value
$226.83M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.24
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$82.44M
EBITDA
-$82.01M
Free cash flow
-$66.66M
Per share
EPS
-$1.88
Free cash flow per share
-$1.52
Book value per share
$2.26
Revenue per share
$0
TBVPS
$3.61
Balance sheet
Total assets
$158.57M
Total liabilities
$41.83M
Debt
$22.19M
Equity
$116.74M
Working capital
$114.39M
Liquidity
Debt to equity
0.19
Current ratio
6.82
Quick ratio
6.73
Net debt/EBITDA
0.43
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-56.2%
Return on equity
-76.4%
Return on invested capital
-78.7%
Return on capital employed
-59.3%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

BDTX stock price

How has the Black Diamond Therapeutics stock price performed over time
Intraday
1%
1 week
-11.23%
1 month
-11.85%
1 year
220.25%
YTD
80.07%
QTD
-0.2%

Financial performance

How have Black Diamond Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$86.46M
Net income
-$82.44M
Gross margin
N/A
Net margin
N/A
The net income has grown by 10% YoY
BDTX's operating income is up by 7% YoY

Growth

What is Black Diamond Therapeutics's growth rate over time

Valuation

What is Black Diamond Therapeutics stock price valuation
P/E
N/A
P/B
2.24
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Black Diamond Therapeutics's EPS has increased by 25% YoY and by 12% QoQ
The P/B is 71% higher than the last 4 quarters average of 1.3 and 23% higher than the 5-year quarterly average of 1.8
The company's equity fell by 13% QoQ

Efficiency

How efficient is Black Diamond Therapeutics business performance
BDTX's return on invested capital is down by 26% year-on-year and by 4.4% since the previous quarter
Black Diamond Therapeutics's ROE has decreased by 20% YoY but it has increased by 2.3% from the previous quarter
The ROA fell by 16% YoY but it rose by 2.4% QoQ

Dividends

What is BDTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BDTX.

Financial health

How did Black Diamond Therapeutics financials performed over time
The quick ratio has contracted by 30% from the previous quarter and by 17% YoY
BDTX's current ratio is down by 30% since the previous quarter and by 19% year-on-year
The debt is 81% smaller than the equity
Black Diamond Therapeutics's debt to equity has decreased by 14% YoY but it has increased by 12% QoQ
The company's equity fell by 13% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.